NASDAQ: ONCROncorus Inc Stock
$0.34+0.02 (+6.25%)
Updated Mar 31, 2023
ONCR Price
$0.34
Fair Value Price
$1.31
Market Cap
$8.98M
52 Week Low
$0.23
52 Week High
$1.90
P/E
-0.12x
P/B
0.15x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$77.42M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.41
Operating Cash Flow
-$62M
Beta
0.7
Next Earnings
May 2, 2023
Ex-Dividend
N/A
Next Dividend
N/A
ONCR Overview
Oncorus Incorporated is developing viral immunotherapies for cancer patients. The company's lead product candidate, ONCR-177 is in Phase I clinical trials for treating various cancers. ONCR-GBM is a preclinical oHSV program for treating brain cancer through intratumoral injection. Oncorus was incorporated in 2015 and is headquartered in Cambridge, MA.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ONCR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ONCR ($0.34) is undervalued by 73.68% relative to our estimate of its Fair Value price of $1.31 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ONCR ($0.34) is significantly undervalued by 73.68% relative to our estimate of its Fair Value price of $1.31 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ONCR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ONCR due diligence checks available for Premium users.
Be the first to know about important ONCR news, forecast changes, insider trades & much more!
ONCR News
Valuation
ONCR fair value
Fair Value of ONCR stock based on Discounted Cash Flow (DCF)
Price
$0.34
Fair Value
$1.31
Undervalued by
73.99%
ONCR ($0.34) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ONCR ($0.34) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ONCR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ONCR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.12x
Industry
18.64x
Market
22.13x
ONCR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.15x
Industry
4.98x
ONCR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ONCR's financial health
Profit margin
Revenue
$0.0
Net Income
-$20.9M
Profit Margin
0%
ONCR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$145.6M
Liabilities
$85.1M
Debt to equity
1.41
ONCR's short-term assets ($64.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ONCR's short-term assets ($64.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ONCR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.1M
Investing
-$1.7M
Financing
$29.0k
ONCR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ONCR vs Biotech Stocks
Oncorus Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.